Open AccessP907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY
Author(s) -
Quach H.,
Leleu X.,
Mateos M.V.,
Usmani S. Z.,
Nooka A. K.,
Goldrick A.,
Najdi R.,
Shu N.,
Facon T.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846500.86746.52
Subject(s) - carfilzomib , medicine , daratumumab , hazard ratio , oncology , lenalidomide , tolerability , multiple myeloma , proportional hazards model , subgroup analysis , confidence interval , adverse effect